Endometriose unter Tamoxifentherapie

Fuith LC, L C Fuith, Lothar C. Fuith, Pflanzl W, W. Pflanzl
Geburtshilfe und Frauenheilkunde · 1995 · vol. 55(06) , pp. 354–355 · doi:10.1055/s-2007-1023333 · PMID:7657147 · W2054221224
article OA: closed CC0
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-14 · read from full text ⓘ

This case report describes a patient who developed endometriosis while undergoing tamoxifen therapy for breast cancer. The authors highlight that although tamoxifen is primarily used as an anti-estrogen, it exhibits estrogen-agonistic effects on the uterus which can lead to pathological changes. The paper notes that these effects are typically associated with an increased risk of endometrial carcinoma but demonstrates here their potential to induce endometriotic lesions. Relevance to endometriosis: This paper is centrally about endometriosis, specifically reporting its development as a side effect of tamoxifen treatment in a breast cancer patient.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Tamoxifen is widely used in anti-oestrogen treatment of breast cancer. Recent reports show that, due to oestrogen-agonistic effects, tamoxifen is associated with endometrial carcinoma. We report on the case of a patient who developed endometriosis during tamoxifen treatment.
Full text 1,053 characters · extracted from oa-doi-fallback · click to expand
Subscribe to RSS Please copy the URL and add it into your RSS Feed Reader. https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000020.xml Geburtshilfe Frauenheilkd 1995; 55(6): 354-355 DOI: 10.1055/s-2007-1023333 DOI: 10.1055/s-2007-1023333 Endometriose unter Tamoxifentherapie Endometriosis During Tamoxifen TreatmentFurther Information Publication History Publication Date: 18 March 2008 (online) Zusammenfassung Tamoxifen wird als anti-östrogene Therapie beim Mammakarzinom verwendet. Aktuelle Berichte zeigen jedoch, daß Tamoxifen auch infolge östrogenagonistischer Effekte mit dem gehäuften Auftreten von Endometriumkarzinomen in Zusammenhang steht. Wir berichten im folgenden über eine Patientin, die unter Tamoxifentherapie eine Endometriose entwickelt hat. Abstract Tamoxifen is widely used in anti-oestrogen treatment of breast cancer. Recent reports show that, due to oestrogen-agonistic effects, tamoxifen is associated with endometrial carcinoma. We report on the case of a patient who developed endometriosis during tamoxifen treatment.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Breast Neoplasms Carcinoma, Ductal, Breast Endometriosis Ovarian Diseases Tamoxifen Breast Neoplasms Carcinoma, Ductal, Breast Chemotherapy, Adjuvant Endometriosis Endometriosis Female Humans Middle Aged Ovarian Diseases Ovarian Diseases Ovary Ovary Tamoxifen Tamoxifen

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-09-01T06:12:48.306406+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:11:13.665691+00:00
unpaywall
last seen: 2026-09-01T06:29:04.589233+00:00
License: CC0 · commercial use OK